In the PRAD tumour group, 10,174 eGenes were detected to be derived from 1-5 eccDNA types, 1,151 eGenes were derived from 6–10 eccDNA types, 359 eGenes were derived from 11–15 eccDNA types, 141 eGenes were derived from 16–20 eccDNA types, 65 eGenes were derived from 21–25 eccDNAs, 37 eGenes were derived from 26–30 eccDNAs, 17 eGenes were derived from 31–35 eccDNAs, 8 eGenes were derived from 36–40 eccDNAs, 10 eGenes were derived from 40–45 eccDNAs, and five eGenes were derived from more than 45 eccDNA types, namely CNTNAP2, TRAPPC9, DAB1, RBFOX1 and CAMTA1 (Figure 1C; Supplementary Table 4). This evidence concerns the gene CNTNAP2 and prostate adenocarcinoma.